GMAB vs. TAK, TEVA, ALNY, RPRX, BMRN, BGNE, VTRS, SRPT, UTHR, and RDY
Should you be buying Genmab A/S stock or one of its competitors? The main competitors of Genmab A/S include Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), Viatris (VTRS), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry.
Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.
In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.55 beat Takeda Pharmaceutical's score of 0.27 indicating that Genmab A/S is being referred to more favorably in the media.
Genmab A/S received 43 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 60.85% of users gave Genmab A/S an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Genmab A/S currently has a consensus target price of $48.50, suggesting a potential upside of 71.99%. Takeda Pharmaceutical has a consensus target price of $14.00, suggesting a potential upside of 4.87%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.
7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Genmab A/S has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Takeda Pharmaceutical has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.
Genmab A/S has a net margin of 30.74% compared to Takeda Pharmaceutical's net margin of 6.18%. Genmab A/S's return on equity of 18.90% beat Takeda Pharmaceutical's return on equity.
Summary
Genmab A/S beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.
Get Genmab A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Genmab A/S Competitors List
Related Companies and Tools